EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 116 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal September 1, 2022 Five Questions With…Jessica, Katie, and Melanie July 21, 2022 Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer... February 4, 2020 Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of... February 2, 2022 Load more HOT NEWS Being Diagnosed With a Childhood Cancer As an Adult Led Me... FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and... How I Coped With My Own Cancer Diagnoses As an Oncologist
